A new method is found to determine an increased risk for side effects of an SSRI treatment in a person by genotyping the person for the presence of the 102 C/C DNA sequence in the 5-HT.sub.2A receptor gene. This provides for a method to improve the treatment of an SSRI responsive disorder and in particular depression.